Skip to main content
letter
. 2019 Apr;104(4):e147–e150. doi: 10.3324/haematol.2018.197277

Figure 2.

Figure 2.

Kaplan-Meier estimates of overall survival of patients with extramedullary disease based on induction therapy. Data from the subset analysis are shown for overall survival for patients with and without extramedullary disease who received protocol-prescribed induction therapy with a standard (45 mg/m2) or high (90 mg/m2) dose of daunorubicin. Data are from the time of randomization at the start of induction therapy. CNSR indicates censored.